Type6 Therapeutics
Biotechnology company developing a new class of bifunctional kinase inhibitors to target historically hard-to-drug cancers using rational engineering to create highly specific, high avidity molecules.
Location
Boston, Massachusetts, USA
Founded
2021
Investors
1
Categories
oncology, therapeutics, kinase-inhibitors, biotech, drug-discovery
Notes
Type6 Therapeutics is a biotechnology company developing a new class of bifunctional kinase inhibitors to target historically hard-to-drug cancers. The company is headquartered in Boston, Massachusetts.
The company's rational engineering approach creates highly specific, high avidity molecules that can target kinases that have been difficult to drug with traditional small molecule approaches. Bifunctional kinase inhibitors combine two mechanisms of action in a single molecule, potentially offering:
- Improved efficacy against resistant tumors
- Better selectivity and reduced off-target effects
- Novel mechanisms to overcome drug resistance
- Targeting of previously undruggable kinases
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Bifunctional kinase inhibitor platform
- Rational engineering approach
- Hard-to-target cancer focus
- High specificity and avidity molecules
- Boston, Massachusetts headquarters
- Founded in 2021
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |